Home
About
About EIPG
The Statute
Bureau and Executive
Past Presidents Advisory Committee
Member States
EIPG Awards
EIPG Award Recipients
Information
Guides and Codes
Position Papers
Education
Media Library
Presentations
Photo Gallery
News
From the Bureau
Newsletter
Business & Policies
Regulatory Affairs
Technology & Research
EU Focus
News from EIPG
Members
Members Area
Webinars
EIPG Journal
Brexit
Contact us
Consultation Deadlines
Home
/
Consultation Deadlines
6th April 2020
FDA draft guidance for industry entitled “Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products—Questions and Answers.”
7th April 2020
FDA draft guidance for industry entitled “Biosimilars and Interchangeable Biosimilars: Licensure for Fewer Than All Conditions of Use for Which the Reference Product Has Been Licensed.”
17th April 2020
EMA Scientific guideline: Reflection paper on good manufacturing practice and marketing authorisation holders, draft: consultation open.
20th April 2020
FDA draft guidance entitled “Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics.”
30th April 2020
EMA Scientific guideline: CVMP reflection paper on promoting the authorisation of alternatives to antimicrobials in the EU, draft: consultation open.
5th May 2020
FDA draft guidance for industry entitled “Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment.”
20th May 2020
European Commission second targeted stakeholders’ consultation on the revision of Annex 1, on manufacturing of sterile medicinal products, of Eudralex volume 4.
News from EIPG
A new member within EIPG
The EU Parliament voted its position on the Unitary SPC
Reform of pharma legislation: the debate on regulatory data protection
Environmental sustainability: the EIPG perspective
How AI is Changing the Pharma Industry and the Industrial Pharmacist’s Role
Generative AI in drug development
PGEU annual medicine shortages report